首页 > 最新文献

Current Opinion in Supportive and Palliative Care最新文献

英文 中文
Osteoradionecrosis - an old problem with new consequences. 骨坏死--老问题,新后果。
IF 1.9 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-03-01 Epub Date: 2024-12-22 DOI: 10.1097/SPC.0000000000000690

Purpose of review: Osteoradionecrosis (ORN) is a devasting complication of radiation therapy (RT), especially in head and neck cancers (HNC), and is still poorly understood. The aim of this review is to report its incidence and consider the risk factors associated with ORN to highlight prevention strategies to decrease its incidence.

Recent findings: The average incidence of ORN is between 2% and 23%, with incidence decreasing in more recent years with the introduction of modern RT technology and better oral health care. Smoking, diabetes mellitus, oropharyngeal and oral cavity cancers, pre- and post-RT dental extractions and a total radiation dose of over 60 Gy were all identified as risk factors for ORN. In prevention, strategies were mainly structured around minimising risk factors or targeting possible mechanisms of ORN's pathophysiology.

Summary: At present, the controversy surrounding the risk factors and pathogenesis of ORN makes it difficult to establish a set of prevention guidelines for its incidence. In order to achieve this, more research examining its aetiology must be conducted as well as a universal staging system within which ORN may be classified.

综述的目的:骨坏死(ORN)是放射治疗(RT),尤其是头颈部癌症(HNC)的一种严重并发症,但人们对其了解甚少。本综述旨在报告其发病率,并考虑与ORN相关的风险因素,以强调降低其发病率的预防策略:ORN 的平均发病率在 2% 到 23% 之间,近年来随着现代 RT 技术的引入和口腔保健的改善,发病率有所下降。吸烟、糖尿病、口咽癌和口腔癌、RT 前后拔牙以及总辐射剂量超过 60 Gy 都是 ORN 的危险因素。小结:目前,围绕 ORN 的风险因素和发病机制存在争议,因此很难为其发病制定一套预防指南。为此,必须对其病因进行更多的研究,并建立一个通用的分期系统,以便对 ORN 进行分类。
{"title":"Osteoradionecrosis - an old problem with new consequences.","authors":"","doi":"10.1097/SPC.0000000000000690","DOIUrl":"10.1097/SPC.0000000000000690","url":null,"abstract":"<p><strong>Purpose of review: </strong>Osteoradionecrosis (ORN) is a devasting complication of radiation therapy (RT), especially in head and neck cancers (HNC), and is still poorly understood. The aim of this review is to report its incidence and consider the risk factors associated with ORN to highlight prevention strategies to decrease its incidence.</p><p><strong>Recent findings: </strong>The average incidence of ORN is between 2% and 23%, with incidence decreasing in more recent years with the introduction of modern RT technology and better oral health care. Smoking, diabetes mellitus, oropharyngeal and oral cavity cancers, pre- and post-RT dental extractions and a total radiation dose of over 60 Gy were all identified as risk factors for ORN. In prevention, strategies were mainly structured around minimising risk factors or targeting possible mechanisms of ORN's pathophysiology.</p><p><strong>Summary: </strong>At present, the controversy surrounding the risk factors and pathogenesis of ORN makes it difficult to establish a set of prevention guidelines for its incidence. In order to achieve this, more research examining its aetiology must be conducted as well as a universal staging system within which ORN may be classified.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":" ","pages":"v-vii"},"PeriodicalIF":1.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139089132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Virtual geriatric and frailty assessment for older adults with cancer. 为患有癌症的老年人提供虚拟老年病学和虚弱评估。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-03-01 Epub Date: 2024-01-26 DOI: 10.1097/SPC.0000000000000696
Isabel Tejero, Eva Amor, Olga Vázquez-Ibar

Purpose of review: Since SARS-CoV2 pandemic, many specialties have introduced virtual assessments within clinical practice. Conducting an online geriatric assessment, or relying on self-reported questionnaires, may be more challenging than a conventional medical appointment. This review aims to discuss the state of research on virtual assessment and self-reported questionnaires in the general geriatric population and specifically in Oncology.

Recent findings: Virtual assessment of older adults has been the focus of two separate position papers. Aside from videoconferences or phone appointments, self-reported questionnaires have emerged in recent years as reliable tools to screen for frailty and triage patients who would benefit from a comprehensive in-person assessment, with adequate correlation with in-person tests, good acceptance by the respondents and being well received by healthcare providers. Although some have been tried in geriatric oncology, many still lack validation, and their widespread use may be limited by digital literacy, cognitive impairment, and social supports.

Summary: The development, validation and adoption of self-reported questionnaires and virtual assessment in the care of older adults with cancer may overcome the staffing limitations and time constrains that frequently hampers the widespread evaluation of this population to improve their care.

审查目的:自 SARS-CoV2 大流行以来,许多专科在临床实践中引入了虚拟评估。与传统的医疗预约相比,进行在线老年病评估或依赖自我报告问卷可能更具挑战性。本综述旨在讨论在普通老年医学人群中,特别是在肿瘤学中,虚拟评估和自我报告问卷的研究现状:对老年人的虚拟评估是两份独立立场文件的重点。除了视频会议或电话预约外,近年来还出现了自我报告问卷,作为筛查虚弱和分流病人的可靠工具,这些病人将受益于全面的现场评估,与现场测试有足够的相关性,被调查者接受度高,并受到医疗服务提供者的欢迎。总结:在老年肿瘤患者的护理过程中,开发、验证和采用自我报告问卷和虚拟评估可能会克服人员限制和时间限制,这些因素经常阻碍对这一人群进行广泛评估,从而改善他们的护理。
{"title":"Virtual geriatric and frailty assessment for older adults with cancer.","authors":"Isabel Tejero, Eva Amor, Olga Vázquez-Ibar","doi":"10.1097/SPC.0000000000000696","DOIUrl":"10.1097/SPC.0000000000000696","url":null,"abstract":"<p><strong>Purpose of review: </strong>Since SARS-CoV2 pandemic, many specialties have introduced virtual assessments within clinical practice. Conducting an online geriatric assessment, or relying on self-reported questionnaires, may be more challenging than a conventional medical appointment. This review aims to discuss the state of research on virtual assessment and self-reported questionnaires in the general geriatric population and specifically in Oncology.</p><p><strong>Recent findings: </strong>Virtual assessment of older adults has been the focus of two separate position papers. Aside from videoconferences or phone appointments, self-reported questionnaires have emerged in recent years as reliable tools to screen for frailty and triage patients who would benefit from a comprehensive in-person assessment, with adequate correlation with in-person tests, good acceptance by the respondents and being well received by healthcare providers. Although some have been tried in geriatric oncology, many still lack validation, and their widespread use may be limited by digital literacy, cognitive impairment, and social supports.</p><p><strong>Summary: </strong>The development, validation and adoption of self-reported questionnaires and virtual assessment in the care of older adults with cancer may overcome the staffing limitations and time constrains that frequently hampers the widespread evaluation of this population to improve their care.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":" ","pages":"16-21"},"PeriodicalIF":2.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139567552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitigating late effects in cancer survivors: harnessing personalised medicine and new models of care. 减轻癌症幸存者的晚期影响:利用个性化医疗和新的护理模式。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-03-01 Epub Date: 2024-01-31 DOI: 10.1097/SPC.0000000000000693
Joanne Bird, Sara Faithfull
{"title":"Mitigating late effects in cancer survivors: harnessing personalised medicine and new models of care.","authors":"Joanne Bird, Sara Faithfull","doi":"10.1097/SPC.0000000000000693","DOIUrl":"10.1097/SPC.0000000000000693","url":null,"abstract":"","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"18 1","pages":"27-29"},"PeriodicalIF":2.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139673381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supportive and palliative care for older adults with cancer; facilitating person-centred, age friendly care. 为患有癌症的老年人提供支持性和姑息治疗;促进以人为本的老年友好型护理。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-03-01 Epub Date: 2024-01-31 DOI: 10.1097/SPC.0000000000000689
Christopher B Steer, Schroder Sattar, Ines Menjak
{"title":"Supportive and palliative care for older adults with cancer; facilitating person-centred, age friendly care.","authors":"Christopher B Steer, Schroder Sattar, Ines Menjak","doi":"10.1097/SPC.0000000000000689","DOIUrl":"10.1097/SPC.0000000000000689","url":null,"abstract":"","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"18 1","pages":"1-2"},"PeriodicalIF":2.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139673382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age-friendly healthcare: integrating the 4Ms to enable age-friendly cancer care. 老年友好型医疗保健:整合 4Ms 以实现老年友好型癌症护理。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-03-01 Epub Date: 2024-01-04 DOI: 10.1097/SPC.0000000000000687
Oliver Hodge, Tshepo Rasekaba, Irene Blackberry, Christopher B Steer

Purpose of review: There is a growing movement towards person-centred, age-friendly healthcare in the care of older adults, including those with cancer. The Age-Friendly Health Systems (AFHS) initiative uses the 4Ms framework to enable this change. This review documents the utility and implications of 4Ms implementation across different settings, with a particular focus on cancer care.

Recent findings: The AFHS initiative 4Ms framework uses a set of core, evidence-based guidelines (focussing on What Matters, Medication, Mentation and Mobility) to improve person-centred care. The successful implementation of the 4Ms has been documented in many different healthcare settings including orthopaedics primary care, and cancer care. Implementation of the 4Ms framework into existing workflows complements the use of geriatric assessment to improve care of older adults with cancer. Models for implementation of the 4Ms within a cancer centre are described. Active engagement and education of healthcare providers is integral to success. Solutions to implementing the What Matters component are addressed.

Summary: Cancer centres can successfully implement the 4Ms framework into existing workflows through a complex change management process and development of infrastructure that engages healthcare providers, facilitating cultural change whilst employing quality improvement methodology to gradually adapt the status quo to age-friendly processes.

审查目的:在包括癌症患者在内的老年人护理方面,以人为本、对老年人友好的医疗保健运动日益兴起。老年友好型医疗系统(AFHS)倡议采用 4Ms 框架来促成这一变革。本综述记录了在不同环境下实施 4Ms 的效用和影响,尤其关注癌症护理:AFHS 倡议的 4Ms 框架采用了一套以证据为基础的核心指南(侧重于 "重要事项"、"用药"、"指导 "和 "移动性"),以改善以人为本的护理。在许多不同的医疗机构,包括骨科初级保健和癌症护理机构,都有成功实施 4Ms 的记录。在现有的工作流程中实施 4Ms 框架是对老年评估的补充,以改善对癌症老年人的护理。介绍了在癌症中心实施 4Ms 的模式。医疗服务提供者的积极参与和教育是成功的关键。摘要:癌症中心可以通过复杂的变革管理过程和基础设施的发展,将 4Ms 框架成功应用到现有的工作流程中,让医疗服务提供者参与其中,促进文化变革,同时采用质量改进方法,逐步将现状调整为适合老年人的流程。
{"title":"Age-friendly healthcare: integrating the 4Ms to enable age-friendly cancer care.","authors":"Oliver Hodge, Tshepo Rasekaba, Irene Blackberry, Christopher B Steer","doi":"10.1097/SPC.0000000000000687","DOIUrl":"10.1097/SPC.0000000000000687","url":null,"abstract":"<p><strong>Purpose of review: </strong>There is a growing movement towards person-centred, age-friendly healthcare in the care of older adults, including those with cancer. The Age-Friendly Health Systems (AFHS) initiative uses the 4Ms framework to enable this change. This review documents the utility and implications of 4Ms implementation across different settings, with a particular focus on cancer care.</p><p><strong>Recent findings: </strong>The AFHS initiative 4Ms framework uses a set of core, evidence-based guidelines (focussing on What Matters, Medication, Mentation and Mobility) to improve person-centred care. The successful implementation of the 4Ms has been documented in many different healthcare settings including orthopaedics primary care, and cancer care. Implementation of the 4Ms framework into existing workflows complements the use of geriatric assessment to improve care of older adults with cancer. Models for implementation of the 4Ms within a cancer centre are described. Active engagement and education of healthcare providers is integral to success. Solutions to implementing the What Matters component are addressed.</p><p><strong>Summary: </strong>Cancer centres can successfully implement the 4Ms framework into existing workflows through a complex change management process and development of infrastructure that engages healthcare providers, facilitating cultural change whilst employing quality improvement methodology to gradually adapt the status quo to age-friendly processes.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":" ","pages":"9-15"},"PeriodicalIF":2.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy. 持续性紫杉类药物诱发的周围神经病变的发生率、描述、预测因素和后果。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-06 DOI: 10.1097/spc.0000000000000684
Daniel L Hertz
This review aims to provide insights into persistent taxane-induced peripheral neuropathy (TIPN). The primary objective is to describe the incidence, predictors, and consequences of TIPN lasting at least 1 year after the end of taxane treatment.
本综述旨在深入探讨持续性紫杉类药物诱导的周围神经病变(TIPN)。主要目的是描述在紫杉类药物治疗结束后至少持续一年的 TIPN 的发生率、预测因素和后果。
{"title":"Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy.","authors":"Daniel L Hertz","doi":"10.1097/spc.0000000000000684","DOIUrl":"https://doi.org/10.1097/spc.0000000000000684","url":null,"abstract":"This review aims to provide insights into persistent taxane-induced peripheral neuropathy (TIPN). The primary objective is to describe the incidence, predictors, and consequences of TIPN lasting at least 1 year after the end of taxane treatment.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"35 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138823630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exercise interventions for frail older adults with cancer. 对患有癌症的体弱老年人进行运动干预。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-06 DOI: 10.1097/spc.0000000000000685
Schroder Sattar, Kristen R Haase, Kayoung Lee, Kristin L Campbell
Frailty is prevalent in older adults with cancer and can lead to complications during cancer treatment and poor health outcomes. Exercise has been shown to be a promising strategy to mitigate frailty and slow the accumulation of functional impairment in the general geriatric population. In this review, we present a discussion on the state of the science of exercise interventions for frail older adults with cancer. This review is timely and relevant given the aging of the population and corresponding increase in proportion of older adults living with cancer.
虚弱在患有癌症的老年人中很普遍,会导致癌症治疗期间的并发症和不良的健康后果。在普通老年人群中,运动已被证明是缓解虚弱和减缓功能障碍累积的有效策略。在这篇综述中,我们讨论了针对体弱的老年癌症患者进行运动干预的科学现状。考虑到人口老龄化以及患癌老年人比例的相应增加,本综述具有及时性和相关性。
{"title":"Exercise interventions for frail older adults with cancer.","authors":"Schroder Sattar, Kristen R Haase, Kayoung Lee, Kristin L Campbell","doi":"10.1097/spc.0000000000000685","DOIUrl":"https://doi.org/10.1097/spc.0000000000000685","url":null,"abstract":"Frailty is prevalent in older adults with cancer and can lead to complications during cancer treatment and poor health outcomes. Exercise has been shown to be a promising strategy to mitigate frailty and slow the accumulation of functional impairment in the general geriatric population. In this review, we present a discussion on the state of the science of exercise interventions for frail older adults with cancer. This review is timely and relevant given the aging of the population and corresponding increase in proportion of older adults living with cancer.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"35 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138823591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms inherent in acute-to-chronic pain after surgery - risk, diagnostic, predictive, and prognostic factors. 手术后急性到慢性疼痛的内在机制——风险、诊断、预测和预后因素。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-09-08 DOI: 10.1097/SPC.0000000000000673
Daniela C Rosenberger, Daniel Segelcke, Esther M Pogatzki-Zahn

Purpose of review: Pain is an expected consequence of a surgery, but it is far from being well controlled. One major complication of acute pain is its risk of persistency beyond healing. This so-called chronic post-surgical pain (CPSP) is defined as new or increased pain due to surgery that lasts for at least 3 months after surgery. CPSP is frequent, underlies a complex bio-psycho-social process and constitutes an important socioeconomic challenge with significant impact on patients' quality of life. Its importance has been recognized by its inclusion in the eleventh version of the ICD (International Classification of Diseases).

Recent findings: Evidence for most pharmacological and non-pharmacological interventions preventing CPSP is inconsistent. Identification of associated patient-related factors, such as psychosocial aspects, comorbidities, surgical factors, pain trajectories, or biomarkers may allow stratification and selection of treatment options based on underlying individual mechanisms. Consequently, the identification of patients at risk and implementation of individually tailored, preventive, multimodal treatment to reduce the risk of transition from acute to chronic pain is facilitated.

Summary: This review will give an update on current knowledge on mechanism-based risk, prognostic and predictive factors for CPSP in adults, and preventive and therapeutic approaches, and how to use them for patient stratification in the future.

综述目的:疼痛是手术的预期结果,但远未得到很好的控制。急性疼痛的一个主要并发症是其持续性超过治愈的风险。这种所谓的慢性术后疼痛(CPSP)被定义为手术后持续至少3个月的新的或增加的疼痛。CPSP频繁发生,是一个复杂的生物-心理-社会过程的基础,是一项重要的社会经济挑战,对患者的生活质量有重大影响。它的重要性已被纳入第十一版ICD(国际疾病分类)。最近的研究结果:大多数药物和非药物干预措施预防CPSP的证据不一致。识别相关的患者相关因素,如心理社会方面、合并症、手术因素、疼痛轨迹或生物标志物,可以根据潜在的个体机制对治疗方案进行分层和选择。因此,有助于识别有风险的患者,并实施个性化、预防性、多模式的治疗,以降低从急性疼痛向慢性疼痛过渡的风险。综述:这篇综述将更新目前对成人CPSP基于机制的风险、预后和预测因素、预防和治疗方法的了解,以及如何在未来将其用于患者分层。
{"title":"Mechanisms inherent in acute-to-chronic pain after surgery - risk, diagnostic, predictive, and prognostic factors.","authors":"Daniela C Rosenberger, Daniel Segelcke, Esther M Pogatzki-Zahn","doi":"10.1097/SPC.0000000000000673","DOIUrl":"10.1097/SPC.0000000000000673","url":null,"abstract":"<p><strong>Purpose of review: </strong>Pain is an expected consequence of a surgery, but it is far from being well controlled. One major complication of acute pain is its risk of persistency beyond healing. This so-called chronic post-surgical pain (CPSP) is defined as new or increased pain due to surgery that lasts for at least 3 months after surgery. CPSP is frequent, underlies a complex bio-psycho-social process and constitutes an important socioeconomic challenge with significant impact on patients' quality of life. Its importance has been recognized by its inclusion in the eleventh version of the ICD (International Classification of Diseases).</p><p><strong>Recent findings: </strong>Evidence for most pharmacological and non-pharmacological interventions preventing CPSP is inconsistent. Identification of associated patient-related factors, such as psychosocial aspects, comorbidities, surgical factors, pain trajectories, or biomarkers may allow stratification and selection of treatment options based on underlying individual mechanisms. Consequently, the identification of patients at risk and implementation of individually tailored, preventive, multimodal treatment to reduce the risk of transition from acute to chronic pain is facilitated.</p><p><strong>Summary: </strong>This review will give an update on current knowledge on mechanism-based risk, prognostic and predictive factors for CPSP in adults, and preventive and therapeutic approaches, and how to use them for patient stratification in the future.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":" ","pages":"324-337"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10215493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should opioids be used for breathlessness and in whom? A PRO and CON debate of the evidence. 阿片类药物应该用于治疗呼吸困难吗?用于治疗谁?证据的正反辩论。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-10-26 DOI: 10.1097/SPC.0000000000000674
Magnus Ekström, Daisy J A Janssen
Purpose of review The net clinical benefit of opioids for chronic breathlessness has been challenged by recent randomized clinical trials. The purpose was to review and weigh the evidence for and against opioid treatment for chronic breathlessness in people with serious disease. Recent findings Evidence to date on the efficacy and safety of opioids for chronic breathlessness was reviewed. Findings supporting a benefit from opioids in meta-analyses of earlier, mostly smaller trials were not confirmed by recent larger trials. Evidence pertains mostly to people with chronic obstructive pulmonary disease but also to people with pulmonary fibrosis, heart failure, and advanced cancer. Taken together, there is no consistent evidence to generally recommend opioids for severe breathlessness or to identify people who are more likely to benefit. Opioid treatment may be tested in patients with intractable breathlessness and limited other treatment options, such as in end-of-life care. Knowledge gaps were identified and recommendations were made for future research. Summary Key Points Supportive findings of net benefit of opioids for chronic breathlessness in earlier trials have not been confirmed by recent larger randomized clinical trials. There is no evidence that the opioid treatment improves the person’s exercise capacity or quality of life, and it increases the risk of adverse events. Evidence to date does not support that opioids should generally be recommended for treating breathlessness. In people with intractable symptoms and short expected survival, with few or no treatment options, it may still be reasonable to try opioid treatment with the aim to alleviate severe breathlessness. Research is needed to explore the potential benefit of opioids in selected patient groups. Opioids cannot be generally recommended for treating breathlessness based on insufficient evidence for net clinical benefit.
{"title":"Should opioids be used for breathlessness and in whom? A PRO and CON debate of the evidence.","authors":"Magnus Ekström, Daisy J A Janssen","doi":"10.1097/SPC.0000000000000674","DOIUrl":"10.1097/SPC.0000000000000674","url":null,"abstract":"Purpose of review The net clinical benefit of opioids for chronic breathlessness has been challenged by recent randomized clinical trials. The purpose was to review and weigh the evidence for and against opioid treatment for chronic breathlessness in people with serious disease. Recent findings Evidence to date on the efficacy and safety of opioids for chronic breathlessness was reviewed. Findings supporting a benefit from opioids in meta-analyses of earlier, mostly smaller trials were not confirmed by recent larger trials. Evidence pertains mostly to people with chronic obstructive pulmonary disease but also to people with pulmonary fibrosis, heart failure, and advanced cancer. Taken together, there is no consistent evidence to generally recommend opioids for severe breathlessness or to identify people who are more likely to benefit. Opioid treatment may be tested in patients with intractable breathlessness and limited other treatment options, such as in end-of-life care. Knowledge gaps were identified and recommendations were made for future research. Summary Key Points Supportive findings of net benefit of opioids for chronic breathlessness in earlier trials have not been confirmed by recent larger randomized clinical trials. There is no evidence that the opioid treatment improves the person’s exercise capacity or quality of life, and it increases the risk of adverse events. Evidence to date does not support that opioids should generally be recommended for treating breathlessness. In people with intractable symptoms and short expected survival, with few or no treatment options, it may still be reasonable to try opioid treatment with the aim to alleviate severe breathlessness. Research is needed to explore the potential benefit of opioids in selected patient groups. Opioids cannot be generally recommended for treating breathlessness based on insufficient evidence for net clinical benefit.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":" ","pages":"263-269"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10291345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation therapy options in kidney cancer. 肾癌的放射治疗选择。
IF 2.1 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-12-01 Epub Date: 2023-10-26 DOI: 10.1097/SPC.0000000000000683
Nicholas G Zaorsky, Alexander V Louie, Shankar Siva

Purpose of review: In this review, the authors discuss the use of stereotactic body radiation therapy (SBRT) for the treatment of primary and metastatic renal cell carcinoma (RCC).

Recent findings: For primary RCC treated with SBRT, local control is estimated at >95%, and grade 3-4 toxicity is limited at ≤5%. The difference in glomerular filtration rate pretreatment versus posttreatment was about 7.7 ml/min. For metastatic RCC treated with SBRT, the 1-year local control is ~90%. The incidence of any grade 3-4 toxicity is ~1%. Several ongoing trials are evaluating SBRT in combination or in lieu of systemic therapy. There are many unknowns remaining in the treatment of RCC, including tumor prognostication, treatment selection, and treatment delivery.

Summary: Stereotactic body radiation therapy is a safe and effective treatment option for patients with primary and metastatic RCC.

综述目的:在这篇综述中,作者讨论了立体定向身体放射治疗(SBRT)在原发性和转移性肾细胞癌(RCC)治疗中的应用。最近的研究结果:对于用SBRT治疗的原发性肾细胞瘤,局部控制估计>95%,3-4级毒性限制在≤5%。治疗前和治疗后肾小球滤过率的差异约为7.7ml/min。对于SBRT治疗的转移性RCC,1年的局部控制约为90%。任何3-4级毒性的发生率约为1%。几个正在进行的试验正在评估SBRT联合或代替全身治疗。RCC的治疗仍有许多未知因素,包括肿瘤预后、治疗选择和治疗交付。摘要:立体定向身体放射治疗是原发性和转移性RCC患者安全有效的治疗选择。
{"title":"Radiation therapy options in kidney cancer.","authors":"Nicholas G Zaorsky, Alexander V Louie, Shankar Siva","doi":"10.1097/SPC.0000000000000683","DOIUrl":"10.1097/SPC.0000000000000683","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review, the authors discuss the use of stereotactic body radiation therapy (SBRT) for the treatment of primary and metastatic renal cell carcinoma (RCC).</p><p><strong>Recent findings: </strong>For primary RCC treated with SBRT, local control is estimated at >95%, and grade 3-4 toxicity is limited at ≤5%. The difference in glomerular filtration rate pretreatment versus posttreatment was about 7.7 ml/min. For metastatic RCC treated with SBRT, the 1-year local control is ~90%. The incidence of any grade 3-4 toxicity is ~1%. Several ongoing trials are evaluating SBRT in combination or in lieu of systemic therapy. There are many unknowns remaining in the treatment of RCC, including tumor prognostication, treatment selection, and treatment delivery.</p><p><strong>Summary: </strong>Stereotactic body radiation therapy is a safe and effective treatment option for patients with primary and metastatic RCC.</p>","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"17 4","pages":"308-314"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Supportive and Palliative Care
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1